Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2024

This ''Uterine leiomyomata (Uterine Fibroids) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Uterine leiomyomata (Uterine Fibroids) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Uterine leiomyomata (Uterine Fibroids) Understanding

Uterine leiomyomata or fibroids are an extremely common benign neoplasm in women of reproductive age. Although they are benign, they can have a significant impact on the everyday physical and mental well-being of women with this condition. Fibroids originate from uterine smooth muscle cells (myometrium) whose growth is primarily dependent on the levels of circulating estrogen. Further information regarding the pathogenesis of fibroids is poorly understood. Fibroids can either present as an asymptomatic incidental finding on imaging, or symptomatically. Common symptoms include abnormal uterine bleeding, pelvic pain, disruption of surrounding pelvic structures (bowel and bladder), and back pain. Uterine fibroids typically are seen in three significant locations: subserosal (outside the uterus), intramural (inside the myometrium), and submucosal (Inside the uterine cavity). They can further be broken down to pedunculated or not..

Uterine leiomyomata (Uterine Fibroids) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uterine leiomyomata (Uterine Fibroids) pipeline landscape is provided which includes the disease overview and Uterine leiomyomata (Uterine Fibroids) treatment guidelines. The assessment part of the report embraces, in depth Uterine leiomyomata (Uterine Fibroids) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uterine leiomyomata (Uterine Fibroids) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Uterine leiomyomata (Uterine Fibroids). The therapies under development are focused on novel approaches to treat/improve Uterine leiomyomata (Uterine Fibroids).

Uterine leiomyomata (Uterine Fibroids) Emerging Drugs

Fezolinetant: Ogeda
Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women's health disorders. Fezolinetant's mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women.

Uterine leiomyomata (Uterine Fibroids) : Therapeutic Assessment

This segment of the report provides insights about the Uterine leiomyomata (Uterine Fibroids) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Uterine leiomyomata (Uterine Fibroids)

There are approx. 10+ key companies which are developing the therapies Uterine leiomyomata (Uterine Fibroids). The companies which have their Uterine leiomyomata (Uterine Fibroids) drug candidates in the most advanced stage, i.e phase II include Ogeda

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Uterine leiomyomata (Uterine Fibroids) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uterine leiomyomata (Uterine Fibroids) : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uterine leiomyomata (Uterine Fibroids) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uterine leiomyomata (Uterine Fibroids) drugs.

Uterine leiomyomata (Uterine Fibroids) Report Insights

• Uterine leiomyomata (Uterine Fibroids) Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uterine leiomyomata (Uterine Fibroids) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Uterine leiomyomata (Uterine Fibroids) drugs?
• How many Uterine leiomyomata (Uterine Fibroids) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uterine leiomyomata (Uterine Fibroids)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Uterine leiomyomata (Uterine Fibroids) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uterine leiomyomata (Uterine Fibroids) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bayer HealthCare Pharmaceuticals
• Ogeda
• Treadwell Therapeutics
• Contex Therapeutics
• Repros Therapeutics
• Neurocrine Biosciences

Key Products

• Vilaprisan
• Fezolinetant
• CFI 400945
• CTX 030916
• Telapristone
• Elagolix

This product will be delivered within 1-3 business days.